Three (3) patent documents regarding compositions for the treatment regarding coronavirus were recently published: US Patent Application Nos. 20200165630 from Voyager Therapeutics, Inc and 20200179367 from Mymd Pharmaceuticals, Inc. and US Patent No. 10695361 from Gilead Sciences.
Gilead Sciences is by far the biggest assignee and seeing the most success in the market place in the Pharma & Biopharma subcategory on the Pandemics patent radian. Notably, on July 1st, the United States bought almost the entire worldwide stock of the antiviral drug Remdesivir.
Remdesivir does not cure coronavirus but does speed up recovery from a COVID-19 infection and is currently the best treatment against the virus. With other companies issuing patent applications for coronavirus treatments like Voyager Therapeutics and Mymd Pharmaceuticals, there might be new emerging competitors and potential cures at any moment.
Below is a Magic Number® Patent Radian® diagram highlighting the patent documents assigned to Gilead Sciences, Voyager Therapeutics, and Mymd Pharmaceuticals regarding pharmaceutical treatments from 2019-2020. Explore the pandemic sector through the Magic Number® Pandemic Patent Forecast®.
